Basaglar vs. Lantus: How the Insulin Glargines Compare

Basaglar and Lantus are both long-acting insulin glargine products that lower blood sugar in essentially the same way, and clinical trials have consistently shown they produce equivalent results in people with type 1 and type 2 diabetes. Basaglar entered the market as a lower-cost alternative to Lantus, and the real question for most people is not whether one works better than the other but what the practical differences are when it comes to cost, insurance coverage, pharmacy substitution, and the experience of switching between them.

Same Molecule, Different Regulatory Path

Lantus, made by Sanofi, was the original brand-name insulin glargine approved in the United States. Basaglar, made by Eli Lilly, contains the same insulin glargine molecule but arrived on the market later through a regulatory shortcut. In the European Union, Basaglar is classified as a biosimilar, meaning regulators reviewed it under the same framework used for drugs that copy biologic medicines. In the United States, however, Basaglar was approved through a different pathway and is technically classified as a “follow-on” insulin rather than a formal biosimilar.¹ The distinction is mostly bureaucratic. Both pathways required Lilly to demonstrate that Basaglar matched Lantus in how it behaves in the body and how well it controls blood sugar. For patients, the regulatory label matters less than the clinical evidence, and that evidence is strong.

How They Compare in the Body

Before Basaglar reached pharmacies, researchers ran euglycemic clamp studies in healthy volunteers to see whether the two products behaved identically once injected. These studies measure how much insulin gets into the bloodstream and how powerfully it lowers blood sugar over time. The results showed that Basaglar’s absorption and blood-sugar-lowering activity matched Lantus closely, with all key measurements falling well within the standard range used to confirm two drugs are interchangeable.² In plain terms, the two products entered the bloodstream at the same rate, peaked at the same level, and cleared the body on the same schedule.

This matters because insulin glargine’s whole appeal is its long, flat activity profile. It forms tiny clusters under the skin after injection, and those clusters dissolve slowly to provide a steady trickle of insulin over roughly 24 hours. If a copy product dissolved faster or slower, you would see different patterns of blood sugar control and different risks of low blood sugar. The clamp studies confirmed that does not happen with Basaglar.

Clinical Trial Results in Type 1 Diabetes

People with type 1 diabetes depend entirely on injected insulin, so any difference between two insulin products would show up clearly in this group. Randomized trials comparing Basaglar to Lantus in type 1 diabetes found no meaningful difference in HbA1c reduction, the standard measure of blood sugar control over about three months. In one trial, the average HbA1c change was virtually identical between the two groups, with a treatment difference of just 0.02 percentage points.³ Another trial confirmed the same non-inferiority finding, with a treatment difference of about 0.12 percentage points, well within the margin that clinicians consider clinically irrelevant.⁴

A systematic review that pooled results from multiple biosimilar insulin trials, including those involving Basaglar, concluded that all biosimilar insulins met their pre-specified non-inferiority targets compared to the reference products they copied.⁵ Daily insulin doses, self-monitored blood glucose readings, and rates of hypoglycemia were similar across the board. No trial has found a clinically significant advantage for either product over the other.

Clinical Trial Results in Type 2 Diabetes

The ELEMENT 2 trial was the pivotal study for type 2 diabetes. It enrolled 756 patients whose blood sugar was not well controlled on oral medications, randomized them to either Basaglar or Lantus, and followed them for 24 weeks. Both groups saw large drops in HbA1c, with Basaglar reducing it by 1.29 percentage points and Lantus by 1.34 points, a gap small enough that it could easily be due to chance.⁶ There were no differences in fasting blood sugar, the proportion of patients reaching an HbA1c below 7%, weight gain, allergic reactions, or hypoglycemia rates.

A separate trial called ELEMENT 5, which included both insulin-naïve patients and those already on insulin, replicated these findings. At 24 weeks, Basaglar met the non-inferiority bar, with HbA1c changes of 1.25% versus 1.22% for Lantus.⁷ The one small difference that did reach statistical significance was a slightly smaller drop in fasting morning blood sugar with Basaglar, but the clinical relevance of that isolated finding is questionable given that every other measure was equivalent.

A post hoc analysis of the ELEMENT 2 data also looked specifically at whether age mattered. Adults 65 and older responded identically to younger patients, with no differential treatment effect between Basaglar and Lantus in either age group.⁸ This is reassuring because older adults are more vulnerable to hypoglycemia, and any subtle difference between the products would matter more in that population.

Immune Reactions and Antibody Formation

Insulin is a protein, and any protein injected repeatedly can trigger the immune system to produce antibodies against it. Those antibodies could, in theory, blunt the insulin’s effectiveness or cause allergic reactions. This is one of the areas where biosimilar products get scrutinized most carefully, because even small differences in manufacturing can change a protein’s shape enough to alter its immunogenicity.

Head-to-head comparisons found no significant differences in the rate at which patients developed anti-insulin antibodies on Basaglar versus Lantus, and median antibody levels stayed low (under 5%) after 24 weeks in both type 1 and type 2 diabetes.⁹ Longer follow-up over 52 weeks showed the same picture: no treatment differences in the proportion of patients with cross-reactive antibodies or in the levels of those antibodies at any visit.¹⁰ Crucially, even in the few patients who did develop higher antibody levels, those antibodies had no measurable effect on blood sugar control, insulin dose requirements, or hypoglycemia risk. A published review of all available Basaglar data confirmed that the overall safety profile, including immunogenicity, was similar to Lantus without additional safety concerns.¹¹

What Happens When You Switch From Lantus to Basaglar

Clinical trials typically start patients fresh on one product or the other, but in real life the more common scenario is a patient who has been stable on Lantus being switched to Basaglar, often because of insurance changes or formulary decisions. This is where some patients understandably get anxious, and the real-world data on switching is worth examining separately from the trial data.

A U.S. retrospective study tracked patients converted from Lantus to Basaglar and found no significant difference in daily insulin dose at 3, 6, or 12 months after the switch. HbA1c did not change at any time point either.¹² A smaller study from Saudi Arabia similarly found no significant difference in HbA1c or total daily insulin units before and after switching to Basaglar.¹³

A larger Saudi study found that HbA1c actually dropped slightly after switching, from 9.2% to 8.8% in patients who switched completely. The authors wisely noted, though, that without a comparison group of non-switchers, it is impossible to know whether the improvement came from the switch itself or from other factors like closer follow-up or better adherence that often accompany any medication change.¹⁴ A study that followed patients for a full year after switching found adverse event rates, including hypoglycemia and vascular events, were similar between those on Basaglar and those on Lantus.

The overall message from real-world evidence is reassuring: switching from Lantus to Basaglar at the same dose, the standard recommendation, does not cause a meaningful change in blood sugar control or safety.

The Cost Difference

Cost is the main reason Basaglar exists. Insulin prices in the United States have been a persistent source of frustration for patients, and biosimilar or follow-on competitors are one of the tools intended to bring prices down. In the Medicaid system, Basaglar’s reimbursement rates have been roughly 15% to 16% lower than those of Lantus since its market entry, and in the first year and a half after launch, that price gap saved Medicaid more than $70 million on insulin glargine spending.¹⁵

A more recent analysis found that the growing shift from Lantus to Basaglar and other alternatives lowered average monthly insulin glargine spending from about $191 to $147 for patients under 65, with annual savings from biosimilar insulins reaching roughly $19 million in the study population by 2022.¹⁶ Your individual savings depend heavily on your insurance plan, pharmacy benefit design, and whether your insurer covers Basaglar at a preferred tier. Some insurers have moved Lantus off their formulary entirely in favor of Basaglar; others have done the opposite, depending on the rebate deals they have negotiated with manufacturers. The sticker price difference may not reflect what you actually pay at the counter.

Pharmacy Substitution and State Laws

Even when two insulin products are clinically equivalent, whether your pharmacist can automatically swap one for the other depends on the product’s regulatory designation and your state’s laws. In 2021, the FDA granted a formal interchangeability designation to a different insulin glargine biosimilar, Semglee (insulin glargine-yfgn), making it the first insulin product a pharmacist could substitute at the counter without calling the prescriber, in the same way generic drugs are substituted for brand-name pills. Basaglar does not currently hold that interchangeability designation, so in most states a prescription written specifically for Lantus cannot be filled with Basaglar unless the prescriber approves the change.

State substitution laws also play a significant role. A 2025 study found that states with less restrictive substitution laws saw a much larger increase in the market share of the interchangeable biosimilar compared to states that imposed extra requirements like enhanced physician notification or mandatory patient notification.¹⁷ Requirements for the prescriber to be notified about every substitution, including on refills, were the strongest barrier to uptake. If you are trying to switch to a lower-cost option, the practical step is to ask your prescriber to write the prescription specifically for the product you want, rather than relying on pharmacy-level substitution.

The Pen Devices Are Different

One area where Basaglar and Lantus are genuinely not identical is the injection device. Lantus is available in the SoloStar pen and in vials; Basaglar comes in the KwikPen and also in vials. Both pens are disposable and prefilled, but they look and feel different in the hand. The dose dial, the injection button, and the needle attachment mechanism have small ergonomic differences. If you have been using one pen for years, the other one may feel unfamiliar at first. This is not a medical concern, but it is worth spending a minute with your pharmacist or diabetes educator when switching, especially if you have limited dexterity or vision issues that make the mechanics of injection harder.

Storage is effectively the same for both products. Unopened pens or vials should be refrigerated, and once in use, they can be kept at room temperature for up to 28 days. One area of ongoing research involves the stability of biosimilar insulin formulations after the pen is opened. A laboratory study found that different insulin glargine biosimilars varied in how quickly impurities accumulated during in-use storage, and that the rate of aggregation depended partly on how close the product was to its expiration date.¹⁸ The practical takeaway is the same advice that applies to all insulin: do not use a pen or vial past its 28-day in-use window, and do not use product that has been stored improperly or is past its expiration date.

Why Some Patients Report Feeling Different After Switching

Despite all the evidence showing equivalence, online diabetes forums are full of people who say they noticed changes in blood sugar control after switching from Lantus to Basaglar, or vice versa. Some report more overnight lows; others say their fasting numbers crept up. These reports deserve to be taken seriously as lived experience, but it is worth understanding why they occur even when the products are clinically identical.

The most common explanation is the nocebo effect, the opposite of placebo, where expecting a negative outcome from a change actually produces symptoms. When patients are told they are being switched to a “cheaper” version of their insulin, some naturally worry it will not work as well, and that anxiety can influence both how they perceive their blood sugar readings and how carefully they adhere to their routine. Any medication change also tends to prompt closer self-monitoring, which can reveal fluctuations that were always there but were not being noticed.

There are also legitimate individual factors that can cause blood sugar to shift around the time of a switch. A new pen device with slightly different dose accuracy. A change in injection technique or site. Seasonal changes in activity or diet that happen to coincide with the switch. None of these have anything to do with the insulin molecule itself. If your blood sugar does change after switching, it is worth working with your prescriber to adjust your dose rather than assuming the new product is defective. The clinical data consistently shows that when doses are matched, outcomes are matched.

Other Insulin Glargine Products on the Market

Basaglar was the first follow-on insulin glargine in the U.S., but the competitive landscape has expanded. Semglee (insulin glargine-yfgn) arrived with the FDA’s first interchangeability designation for an insulin product, meaning it can be substituted at the pharmacy counter in many states. Rezvoglar (insulin glargine-aglr) is another biosimilar that has entered the market. All of these contain the same insulin glargine molecule and have been held to similar regulatory standards of demonstrating equivalent blood sugar control and safety profiles. A review of available data on follow-on insulins as a class found no clinically relevant differences between any of them and their respective originator products.¹⁹

Lantus itself also has a concentrated sibling, Toujeo, which is insulin glargine at 300 units per milliliter instead of the standard 100. Toujeo is a distinct product with a different pharmacokinetic profile, a flatter and longer duration, and should not be confused with the Basaglar-versus-Lantus comparison. If your prescriber recommends Toujeo, that is a genuinely different clinical decision from choosing between Basaglar and Lantus.

The growing number of insulin glargine options means your choice often comes down to insurance formulary placement and out-of-pocket cost rather than any medical distinction. If your insurer covers Basaglar at a lower copay than Lantus, there is no clinical reason to resist the switch. If your insurer prefers Lantus, the same logic applies in reverse. The molecule is the same. What varies is the business arrangement behind the price tag.